These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 7875147)

  • 1. Role of granulocyte-macrophage colony-stimulating factor as adjuvant treatment in neutropenic patients with bacterial and fungal infection.
    Bodey GP; Anaissie E; Gutterman J; Vadhan-Raj S
    Eur J Clin Microbiol Infect Dis; 1994; 13 Suppl 2():S18-22. PubMed ID: 7875147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized comparison between antibiotics alone and antibiotics plus granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived in cancer patients with fever and neutropenia.
    Anaissie EJ; Vartivarian S; Bodey GP; Legrand C; Kantarjian H; Abi-Said D; Karl C; Vadhan-Raj S
    Am J Med; 1996 Jan; 100(1):17-23. PubMed ID: 8579082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prevention and treatment of febrile neutropenia].
    Montemurro F; Gallicchio M; Aglietta M
    Tumori; 1997; 83(2 Suppl):S15-9. PubMed ID: 9235724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of ganciclovir and granulocyte-macrophage colony-stimulating factor in the treatment of cytomegalovirus retinitis in AIDS patients. The ACTG 073 Team.
    Hardy D; Spector S; Polsky B; Crumpacker C; van der Horst C; Holland G; Freeman W; Heinemann MH; Sharuk G; Klystra J
    Eur J Clin Microbiol Infect Dis; 1994; 13 Suppl 2():S34-40. PubMed ID: 7875151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Very low doses of GM-CSF administered alone or with erythropoietin in aplastic anemia.
    Kurzrock R; Talpaz M; Gutterman JU
    Am J Med; 1992 Jul; 93(1):41-8. PubMed ID: 1626572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial.
    Ravaud A; Chevreau C; Cany L; Houyau P; Dohollou N; Roché H; Soubeyran P; Bonichon F; Mihura J; Eghbali H; Tabah I; Bui BN
    J Clin Oncol; 1998 Sep; 16(9):2930-6. PubMed ID: 9738560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors.
    Mayordomo JI; Rivera F; Díaz-Puente MT; Lianes P; Colomer R; López-Brea M; López E; Paz-Ares L; Hitt R; García-Ribas I
    J Natl Cancer Inst; 1995 Jun; 87(11):803-8. PubMed ID: 7540696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Granulocyte-macrophage colony-stimulating factor in combination with pentavalent antimony for the treatment of visceral Leishmaniasis.
    Badaró R; Nascimento C; Carvalho JS; Badaró F; Russo D; Ho JL; Reed SG; Johnson WD; Jones TC
    Eur J Clin Microbiol Infect Dis; 1994; 13 Suppl 2():S23-8. PubMed ID: 7875148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hematopoietic growth factor (GM-CSF) after autologous bone marrow transplantation. A randomized, double-blind, multicenter study in 91 cases of non-Hodgkin's malignant lymphomas].
    Gorin NC; Coiffier B; Hayat M; Fouillard L; Kuentz M; Flesch M; Colombat P; Boivin P; Slavin S; Lemarié JC
    Presse Med; 1993 Jan; 22(3):109-20. PubMed ID: 8493215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
    Wong SF; Chan HO
    Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of granulocyte-macrophage colony-stimulating factor as adjuvant therapy for fungal infection in patients with cancer.
    Bodey GP; Anaissie E; Gutterman J; Vadhan-Raj S
    Clin Infect Dis; 1993 Oct; 17(4):705-7. PubMed ID: 8268354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of granulocyte-colony stimulating factor on empiric therapy with flomoxef sodium and tobramycin in febrile neutropenic patients with hematological malignancies. Kan-etsu Hematological Disease and Infection Study Group.
    Yoshida M; Karasawa M; Naruse T; Fukuda M; Hirashima K; Oh H; Ninomiya H; Abe T; Saito K; Shishido H; Moriyama Y; Shibata A; Motoyoshi K; Nagata N; Miura Y
    Int J Hematol; 1999 Feb; 69(2):81-8. PubMed ID: 10071455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Granulocyte-macrophage colony-stimulating factor support in therapy of high-risk acute lymphoblastic leukemia in children.
    Saarinen-Pihkala UM; Lanning M; Perkkiö M; Mäkipernaa A; Salmi TT; Hovi L; Vettenranta K
    Med Pediatr Oncol; 2000 May; 34(5):319-27. PubMed ID: 10797353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized trial of granulocyte-macrophage colony-stimulating factor in neonates with sepsis and neutropenia.
    Bilgin K; Yaramiş A; Haspolat K; Taş MA; Günbey S; Derman O
    Pediatrics; 2001 Jan; 107(1):36-41. PubMed ID: 11134431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment costs and quality of life with granulocyte-macrophage colony-stimulating factor in patients with antineoplastic therapy-related febrile neutropenia. Results of a randomised placebo-controlled trial.
    Uyl-de Groot CA; Vellenga E; de Vries EG; Löwenberg B; Stoter GJ; Rutten FF
    Pharmacoeconomics; 1997 Sep; 12(3):351-60. PubMed ID: 10170460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term treatment with GM-CSF in patients with chronic lymphocytic leukemia and recurrent neutropenic infections.
    Itälä M; Pelliniemi TT; Remes K; Vanhatalo S; Vainio O
    Leuk Lymphoma; 1998 Dec; 32(1-2):165-74. PubMed ID: 10037012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group.
    Bunn PA; Crowley J; Kelly K; Hazuka MB; Beasley K; Upchurch C; Livingston R; Weiss GR; Hicks WJ; Gandara DR
    J Clin Oncol; 1995 Jul; 13(7):1632-41. PubMed ID: 7602352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia.
    Vellenga E; Uyl-de Groot CA; de Wit R; Keizer HJ; Löwenberg B; ten Haaft MA; de Witte TJ; Verhagen CA; Stoter GJ; Rutten FF; Mulder NH; Smid WM; de Vries EG
    J Clin Oncol; 1996 Feb; 14(2):619-27. PubMed ID: 8636779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hematopoietic growth factors in patients receiving intensive chemotherapy for malignant disorders: studies of granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-3 (IL-3) and Flt-3 ligand (Flt3L).
    Bruserud O; Foss B; Petersen H
    Eur Cytokine Netw; 2001; 12(2):231-8. PubMed ID: 11399510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost effectiveness of amphotericin B plus G-CSF compared with amphotericin B monotherapy. Treatment of presumed deep-seated fungal infection in neutropenic patients in the UK.
    Flynn TN; Kelsey SM; Hazel DL; Guest JF
    Pharmacoeconomics; 1999 Nov; 16(5 Pt 2):543-50. PubMed ID: 10662479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.